Dr. Jack West: Why the Broader FDA Approval of First Pembrolizumab Monotherapy based on KEYNOTE-042 is an Invitation to Inferior Care in Advanced NSCLC

West Wind (Video)

English - April 19, 2019 11:00 - 20 minutes - 74.9 MB Video - ★★★★★ - 2 ratings
Science Health & Fitness Medicine cancer oncology health science medicine education howard jack west westwind Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Dr. Jed Gorden (Part 2): Defining the Role of Interventional Pulmonology in a New Era of Lung Cancer Management

Next Episode: Dr. Charu Aggarwal (Part 1): Growing Momentum for Plasma-Based NGS Testing in Advanced NSCLC

Dr. Jack West reviews why the new FDA approval of first line pembrolizumab monotherapy for the 1-49% PD-L1 subgroup won on a technicality and now offers a clearly inferior choice compared to far better existing standards for patients with low tumor PD-L1.